Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P 3-dependent mechanisms leading to resistance to PDK1 inhibitors

Biochemical Journal

Volumn 448, Issue 2, 2012, Pages 285-295

  Najafov, Ayaz ^a   Shpiro, Natalia ^a   Alessi, Dario R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

3 Phosphoinositide dependent kinase 1 (PDK1); Akt; Cancer; Hydrophobic motif; Mammalian target of rapamycin (mTOR); PIF pocket; PtdIns(3,4,5)P 3 PIP3

Indexed keywords

ANTINEOPLASTIC AGENT; DOCKING PROTEIN; GSK 2334470; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; INDAZOLES; MICE; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL PHOSPHATES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RECOMBINANT PROTEINS; RIBOSOMAL PROTEIN S6 KINASES; SERINE; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 84869007032     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20121287     Document Type: Article

References (46)

1. Mora, A., Komander, D., Van Aalten, D. M. and Alessi, D. R. (2004) PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell. Dev. Biol. 15, 161-170
2. Pearce, L. R., Alton, G. R., Richter, D. T., Kath, J. C., Lingardo, L., Chapman, J., Hwang, C. and Alessi, D. R. (2010) Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem. J. 431, 245-255
3. Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. and Hemmings, B. A. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15, 6541-6551
4. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H. and Sabatini, D. M. (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. U.S.A. 95, 1432-1437
5. Garcia-Martinez, J. M. and Alessi, D. R. (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416, 375-385
6. Biondi, R. M., Kieloch, A., Currie, R. A., Deak, M. and Alessi, D. R. (2001) The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J. 20, 4380-4390
7. Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
8. Pearce, L. R., Komander, D. and Alessi, D. R. (2010) The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 11, 9-22
9. Collins, B. J., Deak, M., Arthur, J. S., Armit, L. J. and Alessi, D. R. (2003) In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J. 22, 4202-4211
10. Collins, B. J., Deak, M., Murray-Tait, V., Storey, K. G. and Alessi, D. R. (2005) In vivo role of the phosphate groove of PDK1 defined by knockin mutation. J. Cell. Sci. 118, 5023-5034
11. Bayascas, J. R., Sakamoto, K., Armit, L., Arthur, J. S. and Alessi, D. R. (2006) Evaluation of approaches to generate PDK1 tissue specific knock-in mice. J. Biol. Chem. 281, 28772-28781
12. Garcia-Martinez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M. and Alessi, D. R. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29-42
13. Kobayashi, T. and Cohen, P. (1999) Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem. J. 339, 319-328
14. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D. M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175
15. Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D. M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302
16. Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D. et al. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol. 7, 776-789
17. Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F. and Hawkins, P. T. (1997) Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277, 567-570
18. Milburn, C. C., Deak, M., Kelly, S. M., Price, N. C., Alessi, D. R. and Van Aalten, D. M. (2003) Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem. J. 375, 531-538
19. Calleja, V., Alcor, D., Laguerre, M., Park, J., Vojnovic, B., Hemmings, B. A., Downward, J., Parker, P. J. and Larijani, B. (2007) Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol. 5, e95
20. Currie, R. A., Walker, K. S., Gray, A., Deak, M., Casamayor, A., Downes, C. P., Cohen, P., Alessi, D. R. and Lucocq, J. (1999) Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem. J. 337, 575-583
21. Komander, D., Fairservice, A., Deak, M., Kular, G. S., Prescott, A. R., Downes, C. P., Safrany, S. T., Alessi, D. R. and van Aalten, D. M. (2004) Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J. 23, 3918-3928
22. Bayascas, J. R., Wullschleger, S., Sakamoto, K., Garcia-Martinez, J. M., Clacher, C., Komander, D., van Aalten, D. M., Boini, K. M., Lang, F., Lipina, C. et al. (2008) Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol. Cell. Biol. 28, 3258-3272
23. Shiota, C., Woo, J. T., Lindner, J., Shelton, K. D. and Magnuson, M. A. (2006) Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11, 583-589
24. Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J. and Su, B. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137
25. Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J. and Sabatini, D. M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell 11, 859-871
26. Altomare, D. A. and Testa, J. R. (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455-7464
27. Fenton, T. R. and Gout, I. T. (2010) Functions and regulation of the 70kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 43, 47-59
28. Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y. et al. (2009) AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21-32
29. Emerling, B. M. and Akcakanat, A. (2011) Targeting PI3K/mTOR signaling in cancer. Cancer Res. 71, 7351-7359
30. +/- mice. Curr. Biol. 15, 1839-1846
31. Peifer, C. and Alessi, D. R. (2008) Small-molecule inhibitors of PDK1. ChemMedChem 3, 1810-1838
32. Najafov, A., Sommer, E. M., Axten, J. M., Deyoung, M. P. and Alessi, D. R. (2011) Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem. J. 433, 357-369
33. Medina, J. R., Becker, C. J., Blackledge, C. W., Duquenne, C., Feng, Y., Grant, S. W., Heerding, D., Li, W. H., Miller, W. H., Romeril, S. P. et al. (2011) Structure-based design of potent and selective 3-phosphoinositide- dependent kinase-1 (PDK1) inhibitors. J. Med. Chem. 54, 1871-1895
34. Erlanson, D. A., Arndt, J. W., Cancilla, M. T., Cao, K., Elling, R. A., English, N., Friedman, J., Hansen, S. K., Hession, C., Joseph, I. et al. (2011) Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg. Med. Chem. Lett. 21, 3078-3083
35. Bobkova, E. V., Weber, M. J., Xu, Z., Zhang, Y. L., Jung, J., Blume-Jensen, P., Northrup, A., Kunapuli, P., Andersen, J. N. and Kariv, I. (2010) Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. J. Biol. Chem. 285, 18838-18846
36. Ellwood-Yen, K., Keilhack, H., Kunii, K., Dolinski, B., Connor, Y., Hu, K., Nagashima, K., O'Hare, E., Erkul, Y., Di Bacco, A. et al. (2011) PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. Cancer Res. 71, 3052-3065
37. Durocher, Y., Perret, S. and Kamen, A. (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, E9
38. Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P. et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288-298
39. Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R. et al. (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213-223
40. Shah, O. J., Wang, Z. and Hunter, T. (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14, 1650-1656
41. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B. and Cohen, P. (1997) Characterization of a 3-phosphoinositide- dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr. Biol. 7, 261-269
42. Masters, T. A., Calleja, V., Armoogum, D. A., Marsh, R. J., Applebee, C. J., Laguerre, M., Bain, A. J. and Larijani, B. (2010) Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells. Sci. Signaling 3, ra78
43. Thomas, C. C., Deak, M., Alessi, D. R. and van Aalten, D. M. (2002) High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr. Biol. 12, 1256-1262
44. Liu, Q., Kirubakaran, S., Hur, W., Niepel, M., Westover, K., Thoreen, C. C., Wang, J., Ni, J., Patricelli, M. P., Vogel, K. et al. (2012) Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J. Biol. Chem. 287, 9742-9752
45. 1 arrest followed by cell death. Cancer Res. 59, 5808-5814
46. Forbes, S. A., Tang, G., Bindal, N., Bamford, S., Dawson, E., Cole, C., Kok, C. Y., Jia, M., Ewing, R., Menzies, A. et al. (2010) COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652-D657